Novel carbamate derivatives as selective butyrylcholinesterase inhibitors
- PMID: 29529519
- DOI: 10.1016/j.bioorg.2018.03.003
Novel carbamate derivatives as selective butyrylcholinesterase inhibitors
Abstract
Selective butyrylcholinesterase inhibitors could be the promising drug candidates, used in treatment of Alzheimer's disease. The study describes the synthesis and biological activity of novel carbamate derivatives with N-phenylpiperazine, N-benzylpiperazine and 4-benzylpiperidine moieties. Biological studies revealed that most of these compounds displayed significant activity against BuChE. Compound 16 (3-(4-phenyl-piperazin-1-ylmethyl)-phenyl phenylcarbamate) turned out to be the most active (IC50 = 2.00 μM for BuChE). For all synthesized compounds lipophilicity and other physicochemical properties were calculated using computer programs. Relationship between these properties and activity was also checked. Binding mode with enzyme and the ensuing differences in activity were explained by the molecular modeling studies.
Keywords: Biological evaluation; Butyrylcholinesterase; Carbamates; Docking studies; Inhibitor; Physicochemical properties; Synthesis.
Copyright © 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors.Eur J Med Chem. 2010 Dec;45(12):5602-11. doi: 10.1016/j.ejmech.2010.09.010. Epub 2010 Sep 17. Eur J Med Chem. 2010. PMID: 20926161
-
Novel arylcarbamate-N-acylhydrazones derivatives as promising BuChE inhibitors: Design, synthesis, molecular modeling and biological evaluation.Bioorg Med Chem. 2021 Feb 15;32:115991. doi: 10.1016/j.bmc.2020.115991. Epub 2021 Jan 2. Bioorg Med Chem. 2021. PMID: 33440318
-
Synthesis, structural characterization, docking, lipophilicity and cytotoxicity of 1-[(1R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]-3-alkyl carbamates, novel acetylcholinesterase and butyrylcholinesterase pseudo-irreversible inhibitors.Bioorg Med Chem. 2016 Apr 1;24(7):1560-72. doi: 10.1016/j.bmc.2016.02.033. Epub 2016 Feb 26. Bioorg Med Chem. 2016. PMID: 26947959
-
A Comprehensive Review of Cholinesterase Modeling and Simulation.Biomolecules. 2021 Apr 15;11(4):580. doi: 10.3390/biom11040580. Biomolecules. 2021. PMID: 33920972 Free PMC article. Review.
-
Structure, activities and biomedical applications of human butyrylcholinesterase.Protein Pept Lett. 2009;16(10):1215-24. doi: 10.2174/092986609789071207. Protein Pept Lett. 2009. PMID: 19508180 Review.
Cited by
-
Lupeol-3-carbamate Derivatives: Synthesis and Biological Evaluation as Potential Antitumor Agents.Molecules. 2024 Aug 23;29(17):3990. doi: 10.3390/molecules29173990. Molecules. 2024. PMID: 39274838 Free PMC article.
-
Arylaminopropanone Derivatives as Potential Cholinesterase Inhibitors: Synthesis, Docking Study and Biological Evaluation.Molecules. 2020 Apr 10;25(7):1751. doi: 10.3390/molecules25071751. Molecules. 2020. PMID: 32290227 Free PMC article.
-
Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.J Enzyme Inhib Med Chem. 2023 Dec;38(1):2231661. doi: 10.1080/14756366.2023.2231661. J Enzyme Inhib Med Chem. 2023. PMID: 37414563 Free PMC article.
-
Design, synthesis and preliminary biological evaluation of rivastigmine-INDY hybrids as multitarget ligands against Alzheimer's disease by targeting butyrylcholinesterase and DYRK1A/CLK1 kinases.RSC Med Chem. 2024 Feb 20;15(3):963-980. doi: 10.1039/d3md00708a. eCollection 2024 Mar 20. RSC Med Chem. 2024. PMID: 38516603 Free PMC article.
-
Identification of a Novel Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase: In Vitro and In Silico Studies.Pharmaceuticals (Basel). 2023 Jan 9;16(1):95. doi: 10.3390/ph16010095. Pharmaceuticals (Basel). 2023. PMID: 36678592 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources